Abstract:Transforming growth factor-b (TGF-b) was initially discovered by its ability to stimulate immortalized fibroblasts to grow in soft agar, a phenotype associated with expressing cancer-causing genes. Subsequently, it became clear that the ‘‘transforming activity’’ of TGF-b is reversible and can have potent cytostatic effects on normal epithelial cells. TGF-b is now well known for its dual effects in cancer progression; while TGF-b can have suppressive effects on normal and premalignant cells, more advanced cancer cells—frequently exposed to high levels of TGF-b produced by themselves or the stroma—are not only resistant to its cytostatic effects but also stimulated in their invasive and metastatic behavior. TGF-b can do this directly by facilitating epithelial tomesenchymal transition (EMT) and indirectly by acting on its surrounding stroma, promoting angiogenesis and immune evasion (Akhurst and Derynck, 2001). TGF-b signals via cell surface TGF-b type I and type II serine threonine kinase receptors and intracellular SMAD effector proteins. Upon TGF-b receptor activation, SMAD2 and SMAD3 become phosphorylated and form heteromeric complexes with SMAD4. These SMAD complexes can accumulate in the nucleus, where they act as transcriptional regulators. Because SMAD2 does not interact with DNA and the affinity of SMAD3 and SMAD4 for DNA is weak, there is a need for SMADs to partner with other DNAbinding transcription factors. The repertoire of SMAD interaction partners is large and diverse, providing a basis for multi-functionality of TGF-b and its context-dependent effects (Massagué, 2012). TGF-b receptors and SMADs are mutated in certain cancers. Inactivation of tumor suppressor genes, activation of proto-oncogenes, and microenvironmental changes can change the tumor suppressive and the tumor promoting activity of the TGF-b receptor/SMAD pathway. Most cancer patients die of metastasis and, because TGF-b is a strong driver of this process, TGF-b pathway inhibiting agents have been developed and tested in clinical trials. However, these compounds inhibit all TGF-b responses and may elicit unwanted effects. Careful selection of patients is warranted and proper biomarkers are needed to select those patients that will benefit from such systemic TGF-b-targeted therapy. A better understanding of the molecular mechanisms underlying the contextual effects of TGF-b in cancer may allow development of therapeutics selectively inhibiting its pro-oncogenic effects. Previously, Yu and colleagues provided some clues on these mechanisms by demonstrating that the phosphoserine/phosphothreonine-binding protein 14-3-3z, which is overexpressed in more than 40% of breast cancers, can potentiate TGF-b/ SMAD signaling during EMT and breast tumor progression (Lu et al., 2009). 14-33z and the tyrosine kinase receptor ErbB2 were found to cooperate in driving non-invasive ductal carcinoma in situ (DCIS) progression to invasive breast ductal carcinoma (IDC). Breast tumors expressing both ErbB2 and 14-3-3z have a higher incidence of metastasis than those expressing only one of them (Lu et al., 2009). In addition, they found 143-3z downregulated the cell cycle inhibitor p27 and activated phosphoinositide 3-kinase, thereby promoting cancer cell proliferation and survival (Rehman et al., 2014 and references therein).

Data from <i>TGFBI</i> Deficiency Predisposes Mice to Spontaneous Tumor Development

Tgfbi Deficiency Predisposes Mice To Spontaneous Tumor Development

Supplementary Table 1, Figures 1-5 from TGFBI Deficiency Predisposes Mice to Spontaneous Tumor Development

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Supplemetal Data from Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Enhanced Anti-Tumor Response Upon Deficiency of Msn Kinase MINK1 in Mice

The Role of TGFBI in Mesothelioma and Breast Cancer: Association with Tumor Suppression

TGFBI Protein High Expression Predicts Poor Prognosis in Colorectal Cancer Patients.

Data from Genetic Background Controls Tumor Development in <i>Pten</i>-Deficient Mice

The role of TGFBI (βig-H3) in gastrointestinal tract tumorigenesis

Abstract 1344: TGFß, an Inflammation and Immune Suppressor in Tumor Microenvironment and Progression

Mice with Dysfunctional TGF-β Signaling Develop Altered Intestinal Microbiome and Colorectal Cancer Resistant to 5FU.

Knockout of 4.1B Triggers Malignant Transformation in SV40T-immortalized Mouse Embryo Fibroblast Cells.

Supplementary Figures 1-3 from Genetic Background Controls Tumor Development in <i>Pten</i>-Deficient Mice

Cancer Cell Previews 14-3-3 z Turns TGF-b to the Dark Side

Tumor Formation in Mice with Conditional Inactivation of Brca1 in Epithelial Tissues.

Blocking Transforming Growth Factor Beta Signaling In Transgenic Epidermis Accelerates Chemical Carcinogenesis: A Mechanism Associated With Increased Angiogenesis

Tumor-Derived Transforming Growth Factor-Beta Is Critical For Tumor Progression And Evasion From Immune Surveillance

Deficiency of Kif15 gene inhibits tumor growth due to host CD8+T lymphocytes increase

Abstract 5320: Deletion of TGFß signaling in Gr-1+CD11b+ myeloid cells attenuates breast adenocarcinoma progression

Data from &lt;i&gt;TGFBI&lt;/i&gt; Deficiency Predisposes Mice to Spontaneous Tumor Development